A panelist discusses how identifying intermediate-risk patients, managing disease heterogeneity in non–muscle-invasive bladder cancer, and addressing long-term care needs present key challenges in ...

“While there are other treatment options available for treating BPH, there remains a significant need for much less invasive treatment approaches that can preserve and protect the integrity of the ...

Oncology Decoded Live! Advancing Peri-Operative Bladder Cancer Care: Integration of Emerging Evidence into Cli... “Our findings highlight the coordinated interplay between GCN2 and p53 regulation ...

"The increasing expenses associated with bladder cancer treatment highlight wider issues regarding the sustainability of health care expenditures in the US," writes Michael S. Cookson, MD, MMHC, FACS.

A panelist discusses how emerging investigational agents for NMIBC show promise through diverse mechanisms, including oncolytic viruses (CG0070), immune checkpoint inhibitors (durvalumab, sasanlimab), ...

Sasanlimab combined with BCG significantly improved event-free survival in BCG-naïve, high-risk NMIBC patients compared to BCG alone. The CREST trial's results suggest potential paradigm shifts in ...

“Another aspect is how to make this more and more complex diagnostic chain for prostate cancer work in practice, because we now have so [many] more tools than we had a decade ago,” says Tobias ...

"Studying the microbiome overall is challenging because it's dirty science. You have to be incredibly careful with contamination," says Ilaha Isali, MD, MSc, and Laura Bukavina, MD, MPH, MSc. Isali: ...

The test can provide results in 48 minutes to provide diagnostic insights for conditions such as hypogonadism, impotence, polycystic ovarian syndrome, and other androgenital syndromes.

As the year comes to a close, we revisit some of this year’s top content on next-generation imaging agents in urology. The trial is evaluating the diagnostic performance of copper Cu 64 PSMA I&T ...

9MW2821 combined with toripalimab received breakthrough therapy designation for advanced urothelial carcinoma, enhancing development and review processes. Initial study results showed an 87.5% ...

“As long as APPs are properly supported, they will take off and they will change your practice,” says Mark T. Edney, MD. In this video, Mark T. Edney, MD, discusses how to foster a collaborative ...